Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.

Advertisement

Related Content

Novartis Execs Highlight Cosentyx, LCZ696 As Key 2015 Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel